Press Releases

November 19, 2018
Rubius Therapeutics to Present at Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics , Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced today that Pablo J. Cagnoni , M.D., chief executive officer, will present at Evercore ISI HealthCONx
Additional Formats
September 14, 2018
Rubius Therapeutics Added to Russell 2000 and 3000 Indexes

CAMBRIDGE, Mass. , Sept. 14, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced that the company will be added to the quarterly update of the Russell 2000 ® and 3000

Additional Formats
Displaying 1 - 10 of 17